7月31日，人脑工程概念上涨0.27%，今日主力资金流入7729.22万元，概念股14只上涨，19只下跌。 主力资金净流入居前的分别为科大讯飞（2.28亿元）、创新医疗（9399.58万元）、乐普医疗（6230.96 万元）、熵基科技（6031.32万元）、爱朋医疗（3162.54万元）。 来源：金融界 序号代码名称最新价涨跌幅主力净流入主力净占比1002230科大讯飞48.780.762.28亿元8.28%2002173创 新医疗15.347.729399.58万元8.27%3300003乐普医疗15.560.846230.96万元5.49%4301330熵基科技 29.213.86031.32万元12.2%5300753爱朋医疗31.397.283162.54万元5.27%6002195岩山科技5.741.232957.49 万元1.87%7301293三博脑科50.083.582790.86万元3.88%8603610麒盛科技12.662.592028.90万元 9.16%9300678中科信息33.980.651515.56万元3.66%10688273麦澜德33.76-0.591193.99万元9. ...

资金流向方面，今日主力资金净流入9399.58万元，占比成交额8.27%。其中，超大单净流入1.09亿元、 占成交额9.56%，大单净流出1477.02万元、占成交额1.3%，中单净流出流出5820.40万元、占成交额 5.12%，小单净流出3579.17万元、占成交额3.15%。 创新医疗最新一期业绩显示，截至2025一季报，公司营业总收入1.93亿元、同比减少3.98%，归属净利 润1393.74万元，同比减少368.03%，扣非净利润1497.05万元，同比减少452.67%，流动比率1.892、速动 比率1.780、资产负债率18.52%。 天眼查商业履历信息显示，创新医疗管理股份有限公司，成立于2003年，位于绍兴市，是一家以从事卫 生为主的企业。企业注册资本44128.4352万人民币。公司法定代表人为陈海军。 通过天眼查大数据分析，创新医疗管理股份有限公司共对外投资了9家企业，参与招投标项目6次，专利 信息18条，此外企业还拥有行政许可6个。 来源：金融界 金融界消息 截至2025年7月31日收盘，创新医疗（002173）报收于15.34元，上涨7.72%，换手率 18.39%，成交量76.57 ...

Core Viewpoint - The news highlights a significant rise in brain-computer interface (BCI) concept stocks, driven by new pricing mechanisms introduced by the National Healthcare Security Administration (NHSA) to support innovation in pharmaceuticals and medical devices [1] Group 1: Market Reaction - BCI-related stocks such as Innovation Medical are nearing their daily limit up, with other companies like Aipeng Medical, Sanbo Brain Science, Entropy Technology, Qisheng Technology, and Yanshan Technology also experiencing gains [1] Group 2: Policy Changes - The NHSA has established a new pricing mechanism for newly launched drugs, adding over 100 pricing items related to new medical technologies [1] - Specific pricing items for the nervous system have been introduced, including "BCI implantation fees" and "BCI adaptation fees," which will facilitate rapid clinical application and charging once BCI technology is approved for clinical use [1] - Guidelines for ear, nose, and throat (ENT) procedures now include pricing for "cochlear implant fees" and "speech device installation fees," encouraging medical institutions to assist more patients in communication [1] - Pricing items for radiation therapy have been standardized, including "proton therapy" and "heavy ion therapy," promoting the clinical application of advanced medical equipment [1]

消息面上，为支持药品和医疗器械创新发展，国家医保局制定新上市药品首发价格机制，新增了100多 项与医疗新技术相关的价格项目。神经系统类立项指南统一设立"脑机接口置入费""脑机接口适配费"等 价格项目，脑机接口技术成熟获批进入临床后，可快速进入临床应用并收费。耳鼻喉类立项指南统一设 立"人工耳蜗植入费""发音装置安装费"等价格项目，鼓励医疗机构帮助更多患者"听得见、说得出"。放 射治疗类立项指南统一设立"质子放疗""重离子放疗"等价格项目，促进高端医疗设备的临床转化应用。 与此同时，为鼓励药品研发创新，国家医保局还制定了新上市药品首发价格机制。 格隆汇7月31日｜脑机接口概念股拉升，其中，创新医疗逼近涨停，爱朋医疗、三博脑科、熵基科技、 麒盛科技、岩山科技等跟涨。 ...

A股脑机接口概念尾盘异动拉升，爱朋医疗涨超8%，创新医疗、优刻得-W、三博脑科等跟涨。消息面 上，据央视新闻报道，国家医保局支持脑机接口等新技术进入临床并收费。 ...

Group 1 - The core viewpoint of the article highlights that Shenzhen Silicon-based Bionic Technology Co., Ltd. has been awarded the "Best Innovative Medical Device Company of the Year" at the 9th Medical Health Investment Excellence List by Haoyue Capital, recognizing its outstanding performance in the innovative medical device sector [1][3] - The "Medical Health Investment Excellence List" is a prestigious evaluation created by Haoyue Capital, focusing on the comprehensive strength of investment institutions in the medical health industry, including activity levels, transaction volumes, return performance, and post-investment empowerment [3][4] - Silicon-based Bionic was founded in 2015 and specializes in blood glucose monitoring, utilizing implantable medical hardware technology and AI algorithms to innovate and promote continuous monitoring products globally [4][5] Group 2 - The company has a workforce of nearly 700, led by scientists from prestigious institutions such as Tsinghua University, Peking University, Caltech, Princeton, and the University of Washington, showcasing a strong research and operational management background [4][5] - Its flagship product, the Silicon-based Dynamic CGM, is the second globally and the first in China to use second-generation glucose sensor technology, achieving the highest sales among domestic CGM products for several consecutive years [4][5] - The company has made significant investments in R&D, participating in key national projects and being recognized as a "National High-Performance Medical Device Innovation Center" and a "Potential Technology Unicorn Enterprise" in Shenzhen [5][6] Group 3 - The Chinese medical health industry is experiencing a structural recovery in 2025, with increased financing activity and significant milestone transactions, indicating a shift towards high-quality, international, and value-driven medical innovation [5][6] - Silicon-based Bionic aims to uphold its core value of "Innovating Medical Technology, Serving Public Health" and aspires to become a global leader in chronic disease management innovative medical devices [6]

Core Insights - In the first half of this year, China approved 43 innovative drugs and 45 innovative medical devices, representing year-on-year increases of 59% and 87% respectively, indicating that reform policy dividends are transforming into industrial development momentum [1] Regulatory Reforms - Since last year, the National Medical Products Administration (NMPA) has conducted pilot reforms in 11 provincial-level bureaus to optimize the supplementary application process for drugs, reducing the review time for supplementary applications that require inspection from 200 working days to 60 working days [1] - The NMPA is also exploring the completion of clinical trial reviews and approvals for key innovative drugs within 30 working days [1] Product Approvals - In the first half of the year, 70 new pediatric drugs and 21 rare disease drugs were approved [1] Innovation Initiatives - The Ministry of Industry and Information Technology and the NMPA jointly launched an initiative to promote innovation in artificial intelligence medical devices and biomedical materials [1] - The NMPA introduced 10 measures to optimize the full lifecycle supervision to support the innovative development of high-end medical devices, facilitating the market entry of complex and high-difficulty innovative medical devices such as multifocal intraocular lenses and cardiac pulsed field ablation devices [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002173 证券简称：创新医疗 公告编号：2025-048 创新医疗管理股份有限公司 第七届董事会2025年第一次临时会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 创新医疗管理股份有限公司（以下简称"公司"）第七届董事会于2025年7月30日召开了2025年第一次临 时会议。本次会议以现场和通讯表决相结合的方式召开。会议通知于2025年7月28日以书面形式发出。 本次会议由陈海军董事长主持，应出席董事9名，实际出席董事7名，独立董事姚航平、陈文强以通讯表 决方式对会议所议事项进行了审议和表决。本次会议召开符合《公司法》及公司《章程》的规定，合法 有效。 二、董事会会议审议情况 与会董事就议案进行了审议、表决，以9票赞成、0票反对、0票弃权的表决结果一致通过了如下决议： 1、同意选举陈海军为公司第七届董事会董事长、代表公司执行公司事务的董事，任期自本次会议通过 之日起至本届董事会届满之日止。 2、同意选举陈海军、游向东、姚航平为公司第七届董事会战略委员会成员，其 ...

第七届董事会 2025 年第一次临时会议决议公告 证券代码：002173 证券简称：创新医疗 公告编号：2025-048 创新医疗管理股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 二、董事会会议审议情况 与会董事就议案进行了审议、表决，以 9 票赞成、0 票反对、0 票弃权的表 决结果一致通过了如下决议： 董事，任期自本次会议通过之日起至本届董事会届满之日止。 其中陈海军为该委员会召集人。 同意选举姚航平、黄韬、游向东为公司第七届董事会薪酬与考核委员会成员， 其中姚航平为该委员会召集人。 同意选举陈文强、姚航平、阮光寅为公司第七届董事会审计委员会成员，其 中陈文强为该委员会召集人。 同意选举姚航平、陈海军、陈文强为公司第七届董事会提名委员会成员，其 中姚航平为该委员会召集人。 上述委员会成员任期自本次会议通过之日起至本届董事会届满之日止。 届满之日止。 创新医疗管理股份有限公司（以下简称"公司"）第七届董事会于 2025 年 7 月 30 日召开了 2025 年第一次临时会议。本次会议以现场和通讯表决相结合的方 式召开。 ...

关于创新医疗管理股份有限公司 上海市锦天城律师事务所 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于创新医疗管理股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受创新医疗管理股份有限 公司（以下简称"公司"或"创新医疗"）委托，就公司召开 2025 年第二次临时 股东会（以下简称"本次股东会"）的有关事宜，根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《上市公司股东会规则》等法律、法规、规章和其他 规范性文件以及《创新医疗管理股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东会所涉及的相关事项 进行了必要的核查和验证，核查了本所认为出具该法律意见书所需的相关文件、 资料，并参加了公司本 ...